// App-Quantinova.ai

2473 : Combined BET-bromodomain and CDK2 inhibition in MYC-driven medulloblastoma

Researchers

Presenter

  • Sara Bolin

Principal Investigators

  • Anna Borgenvik

  • Camilla Persson

  • Gabriela Rosen

  • Anders Sundstrom

  • Jun Qi

  • James E. Bradner

  • William A. Weiss

  • Yoon-Jae Cho

  • Holger Weishaupt

  • Fredrik J. Swartling

Medical Centers

  • Uppsala University Hospital, Uppsala, Sweden

  • Dana-Farber Cancer Institute, Boston, MA

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Stanford Univ, Palo Alto, CA

Locations

  • United States

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Medulloblastoma

  • Brain cancer

  • Solid malignancies

Biomarkers

  • Cyclin dependent kinase 2

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved